Nanjing Vazyme Biotech Co., Ltd (SHA:688105)
China · Delayed Price · Currency is CNY 18.06
+0.81 (4.70%)
Jul 10, 2026, 3:00 PM CST
Nanjing Vazyme Biotech Stock Forecast
Stock Price Forecast
According to 3 analysts polled by S&P Global, Nanjing Vazyme Biotech stock has a consensus rating of "Strong Buy" and an average price target of ¥18.80. The average 1-year stock price forecast is 4.10% higher than the current stock price, while the lowest is ¥18.00 (-0.33%) and the highest is ¥19.59 (+8.47%).
Price Target: ¥18.80 (+4.10%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Nanjing Vazyme Biotech stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Nov '25 | Dec '25 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 2 | 3 | 3 |
Financial Forecast
Revenue This Year
1.60B
from 1.38B
Increased by 16.05%
Revenue Next Year
1.88B
from 1.60B
Increased by 17.37%
EPS This Year
0.32
from -0.15
EPS Next Year
0.37
from 0.32
Increased by 17.07%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is CNY.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 1.6B | ||
| Avg | 1.6B | ||
| Low | 1.6B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 17.2% | ||
| Avg | 16.0% | ||
| Low | 15.4% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 0.32 | ||
| Avg | 0.32 | ||
| Low | 0.32 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | ||
| Avg | - | ||
| Low | - |